News | November 27, 2021
Fifty-five manufacturers selected for Pharma PLI sector
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Subscribe To Our Newsletter & Stay Updated
